Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7752W HIGH $5.76
Volume
22.57 M
Value Traded
88.46 M
Short % Float
30.17%
Days to Cover
4.4
-5.43%Week
-19.87%1 Month
+15.71%3 Month
+13.65%6 Month
-87.08%5 Year
-89.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.05 B
EPS (TTM)
-0.89
P/E Ratio
-
Ent. Value
1.50 B
Total Shares
536.27 M
Float Shares
536.80 M
Insiders
10.21%
Institutions
56.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RXRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Recursion Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Recursion Pharmaceuticals, Inc.
371Total events
26Upcoming
97Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationREC-4881Presentation
REC-4881 TUPELO data presented in presidential plenary at CGA-IGC Annual Meeting
familial adenomatous polyposis (FAP)source ↗
▲Additional DataREC-4881Clinical Data
Updated TUPELO data: 47% median total polyp burden reduction at 12 weeks, durable off-treatment, activity across GI tract and in polyps >5 mm
familial adenomatous polyposis (FAP)source ↗
▲Safety Data UpdateREC-4881Clinical Data
No new safety signals observed across 26 safety-evaluable patients; no Grade 4/5 TRAEs
familial adenomatous polyposis (FAP)source ↗
▲Full ResultsREC-1245Clinical Data
REC-1245 Phase 1 DAHLIA dose-escalation data update with partial responses
endometrial cancer and hepatocellular carcinoma (solid tumors)source ↗
▲Full ResultsREC-4881Clinical Data
Positive Phase 2 TUPELO data for REC-4881 in FAP presented at CGA-IGC
familial adenomatous polyposis (FAP)source ↗
▲Partnership / LicenseCorporate
Sanofi options first development candidate from Recursion collaboration
immunology (inflammatory disease)source ↗
▲Milestone PaymentCorporate
$10 million milestone payment triggered by Sanofi option
immunology (inflammatory disease)source ↗
▲Topline ReadoutREC-4881Clinical Data
REC-4881 Phase 1b/2 TUPELO topline data: 47% median total polyp burden reduction, 55% upper GI reduction
Familial Adenomatous Polyposis (FAP)source ↗
▲Topline ReadoutREC-1245Clinical Data
REC-1245 Phase 1 DAHLIA data: 2 confirmed partial responses, 91.7% disease control rate at doses ≥45 mg
endometrial cancer and hepatocellular carcinomasource ↗
▲Development Candidate NominationPreclinical
Sanofi options first development candidate from Recursion collaboration
inflammatory diseasesource ↗
▲Milestone PaymentCorporate
$10 million milestone payment triggered by Sanofi option exercise
inflammatory diseasesource ↗
●Pipeline PrioritizationCorporate
Recursion to focus on REC-4881, REC-1245, REC-4539, REC-7735, REC-102; pursue partnerships for REC-617 and REC-3565
▼Equity OfferingCorporate
Pricing of $200 million underwritten offering of 61,540,000 Class A shares at $3.25 per share
▲Safety Data UpdateREC-4881Clinical Data
REC-4881 favorable safety profile: no TRAEs above Grade 3, supports chronic dosing
Familial Adenomatous Polyposis (FAP)source ↗
▲Dose Finding UpdateREC-1245Trial
REC-1245 45 mg QD selected for expansion cohorts including endometrial cancer
endometrial cancer and other solid tumorssource ↗
▲Partnership / LicenseCorporate
Sanofi options first-in-class oral small molecule immunology development candidate from Recursion collaboration
inflammatory diseasesource ↗
▲Additional DataREC-4881Clinical Data
Upper GI polyp burden results from TUPELO announced
familial adenomatous polyposis (FAP)source ↗
▲Topline ReadoutREC-4881Clinical Data
REC-4881 Phase 1b/2 TUPELO topline data: 47% median total polyp burden reduction, 55% upper GI reduction
Familial Adenomatous Polyposis (FAP)source ↗
▲Safety Data UpdateREC-4881Clinical Data
REC-4881 favorable safety profile: no TRAEs above Grade 3, 4 discontinuations due to AEs
Familial Adenomatous Polyposis (FAP)source ↗
▲Topline ReadoutREC-1245Clinical Data
REC-1245 Phase 1 DAHLIA data: 2 confirmed partial responses, 91.7% disease control rate at doses ≥45 mg
endometrial cancer and hepatocellular carcinomasource ↗
▲Dose Finding UpdateREC-1245Trial
45 mg QD selected for REC-1245 expansion cohorts including endometrial cancer
endometrial cancer and other solid tumorssource ↗
▲Partnership / LicenseCorporate
Genentech exercises first Validated Target Option, advancing first neuroscience target into early discovery program
neurosciencesource ↗
●Enrollment UpdateREC-4881Trial
TUPELO now enrolling patients ages 18 and older, plus alternative dosing cohort
Familial Adenomatous Polyposis (FAP)source ↗
●Management ChangeCorporate
Hoifung Poon appointed Chief AI Officer; Donovan Chin appointed SVP Drug Design
●Runway Guidance UpdateCorporate
Reduced 2026 cash operating expense guidance to <$375 million
▲Partnership / LicenseCorporate
Genentech exercises first Validated Target Option in neuroscience collaboration
neurosciencesource ↗
●FDA Feedback ReceivedREC-4881FDA Meeting
Discussions with FDA initiated in 1H26 to define registrational path
Familial Adenomatous Polyposis (FAP)source ↗
◆Management ChangeCorporate
Vicki Goodman, M.D. appointed as Chief Medical Officer effective April 6, 2026
◆Milestone PaymentREV102Corporate
Rallybio eligible for $5M milestone payment upon initiation of dosing in Phase 1 study
hypophosphatasiasource ↗
▲First Patient DosedREC-4539Trial
First patient dosed in Phase 1 ENLYGHT study of REC-4539 (LSD1 inhibitor) in solid tumors
solid tumors, including small cell lung cancer (SCLC)source ↗
◆Timing GuidanceREC-4881Presentation
Regulatory update on registrational pathway for REC-4881 expected in 2H26
familial adenomatous polyposis (FAP)source ↗
◆Timing GuidanceREC-1245Presentation
Additional Phase 1 dose escalation data expected in 2H26 (duplicate)
solid tumorssource ↗
◆Timing GuidanceREC-7735Presentation
Go/no-go decision on Phase 1 initiation for REC-7735 (PI3Kα H1047R) expected in 2H26
◆Timing GuidanceREC-102Presentation
Go/no-go decision on Phase 1 initiation expected in 2H26 (duplicate)
◆Topline ReadoutREC-3565Clinical Data
Early Phase 1 safety and PK monotherapy data for REC-3565 expected
B cell malignanciessource ↗
◆FDA Feedback ReceivedREC-4881FDA Meeting
Discussions with FDA initiated in 1H26; update to define registrational path expected in 2H26
Familial Adenomatous Polyposis (FAP)source ↗
▲Partnership / LicenseCorporate
Expanded strategic partnership with Citeline to advance AI-enabled ClinTech platform
◆Timing GuidancePresentation
Approximately 10 clinical trial readouts expected in next 18 months
◆Management ChangeCorporate
CEO transition: Najat Khan to become CEO, Chris Gibson to become Chairman effective January 1, 2026
Past FDA Catalysts and PDUFA Decisions
How RXRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-02 | REC-4881 (MEK1/2 inhibitor) | Phase 1b/2 data readout | Phase 1b/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 33%
Small Cap(rank 223 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXS74539 Small moleculeNCT07517198 | Solid Tumor | Phase 1 | RECRUITING | 40 | Mar 1, 2029 | ||||||
| REC-7735 Small moleculeNCT07819136 | Solid Tumors | Phase 1/2 | RECRUITING | 90 | Jan 1, 2031 | ||||||
| REC-1245 Small moleculeNCT06678659 | Unresectable | Phase 1/2 | RECRUITING | 170 | Oct 30, 2028 | ||||||
| REC-4881 Small moleculeNCT05552755 | Familial Adenomatous Polyposis | Phase 1/2 | RECRUITING | 67 | Sep 1, 2027 | ||||||
| GTAEXS617 Small moleculeNCT05985655 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1/2 | RECRUITING | 230 | May 1, 2028 | ||||||
| EXS73565 Small moleculeNCT06980116 | Relapsed or Refractory B-cell Malignancies | Phase 1 | RECRUITING | 85 | Dec 1, 2028 | ||||||
| REC-994 Small moleculeCompletedNCT05085561 | Cerebral Cavernous Malformation | Phase 2 | COMPLETED | 62 | Jun 30, 2025 | ||||||
| EXS21546 for Small moleculeCompletedNCT04727138 | Oncology | Phase 1 | COMPLETED | 64 | May 12, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every RXRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| REC-4881 Fast TrackOrphan | familial adenomatous polyposis (FAP) | Phase 2 | 2026-11-02 | 47% median reduction in total polyp burden; 85% of patients maintained reductions below baseline after stopping treatment; 1 in 3 achieving reductions of ≥65%; nearly 1 in 2 patients in the upper GI achieved polyp burden reductions of ≥65%; more than 1 in 3 in the lower GI achieved polyp burden reductions of ≥65%; six of eight patients with polyps >5 mm had reductions in the number of these polyps; four achieved reductions of ≥80%; two whose larger-polyp counts fell from more than 90 polyps to oneRead More | New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk PolypsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HERSHBERG ROBERTDirector | Option | 25,000 187,156 held | $2.22 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RXRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0 % | 606.74 K | 165.32 K |
Ownership Trends
RXRX Short Interest
Shares sold short, counted twice a month.
30.17%
Short % of Float
of tradable shares sold short
161.9M
Shares Sold Short
+2.5% vs prior count
4.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
36.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RXRX ranks across every disease it competes in
Competitive Position is a premium feature
See how RXRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRXRX News
RXRX▼ -5%today
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
Recursion reported positive Phase 2 results for REC-4881, showing significant reductions in polyp burden in FAP patients. The drug demonstrated durable effects even after treatment cessation. Additionally, REC-1245 showed promising activity in endometrial cancer. The company also extended its cash runway into 2029 and appointed Fred Hassan as Chair of the Board.
Read more →RXRX▼ -5%today
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
Recursion (RXRX) presented positive Phase 2 data for REC-4881 at the CGA-IGC meeting. The study showed a 47% median reduction in polyp burden among patients with familial adenomatous polyposis (FAP) after 12 weeks of treatment. Notably, 85% of patients maintained reductions below baseline after stopping treatment. The company plans to initiate a registrational trial in late 2027.
Read more →RXRX▼ -5%today
Recursion Appoints Fred Hassan as Chair of the Board
Recursion appointed Fred Hassan as Board Chair, effective October 31, 2026. Hassan brings over four decades of pharmaceutical experience, including leading Schering-Plough to sales growth. He previously helped BridgeBio secure FDA approval for Attruby. The Board believes his operating background will aid Recursion's clinical advancement.
Read more →RXRX▲ +6.6%on this news
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Recursion will host a webinar on November 3, 2026, to discuss updated data on REC-4881 and provide third quarter financial results. The event will feature expert panels and patient advocates discussing familial adenomatous polyposis (FAP). The company aims to address unmet needs in FAP with its investigational therapies.
Read more →RXRX▲ +11.2%on this news
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion Pharmaceuticals announced that Sanofi has optioned its first development candidate from their collaboration, triggering a $10 million milestone payment. This candidate, aimed at treating inflammatory diseases, is set to enter phase 1 clinical trials in 2027. The collaboration has achieved significant financial milestones and aims to advance multiple programs in immunology and oncology.
Read more →RXRX▲ +11.2%on this newsshared move
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Pharmaceuticals has priced an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share, aiming to raise approximately $200 million. The offering is set to close on October 16, 2026, subject to customary conditions. Major healthcare investors are participating, supporting Recursion's AI-driven drug discovery initiatives.
Read more →RXRX▲ +11.2%on this newsshared move
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion has announced a $200 million follow-on offering, backed by leading healthcare investors. The company provided updates on its clinical pipeline, highlighting positive Phase 1b/2 data for REC-4881 in Familial Adenomatous Polyposis and encouraging results for REC-1245 in endometrial cancer. Additionally, a partnership with Sanofi has been established for a new immunology candidate, further enhancing Recursion's development prospects.
Read more →RXRXRecursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion reported its second quarter financial results, highlighting significant advancements in its drug discovery platform and collaborations with Genentech and Sanofi. The company is progressing with its neuroscience target and has reduced its cash operating expense guidance for 2026. Despite a net loss, the collaboration with Genentech marks a pivotal point in uncovering novel therapeutic opportunities.
Read more →RXRXRecursion to Participate in Upcoming Investor Conferences
Recursion (NASDAQ: RXRX) has announced its participation in two upcoming investor conferences: the Bank of America 2026 SMID Cap Executive Insights Event on August 11, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is recognized for its advanced AI-driven drug discovery platform and diverse investigational medicines portfolio.
Read more →RXRX▲ +6%on this newsshared move
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion (Nasdaq: RXRX) announced the approval of inducement RSU awards for 24 new employees, totaling 3,234,866 shares. This grant is part of the company's 2024 Inducement Equity Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over time, promoting employee retention and engagement.
Read more →RXRXRecursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Recursion Pharmaceuticals will report its second quarter 2026 financial results on August 5, 2026. The company plans to release these updates before the market opens on that Wednesday. An earnings call will follow at 8:00 AM Eastern Time. Investors can access the live stream via the company’s social media channels.
Read more →RXRXRecursion To Participate In Upcoming Investor Conferences
Recursion To Participate In Upcoming Investor Conferences
Read more →RXRXRecursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Recursion Reports Grant Of Inducement Awards As Permitted By The Nasdaq Listing Rules
Read more →RXRXRecursion Reports First Quarter Financial Results and Provides Business Update
Recursion Pharmaceuticals (RXRX) reported strong progress in its clinical pipeline during Q1 2026, achieving key milestones across various programs. Notably, REC-1245 showed promising safety and pharmacokinetics in solid tumors, while REC-4881 exhibited significant efficacy in Phase 2 trials. The company continues to maintain a solid cash position, projecting operational sustainability into early 2028.
Read more →RXRXRecursion Announces Board Transition
Recursion has announced that Chris Gibson, Ph.D., will step down from the Board of Directors but will serve as an advisor. CEO Najat Khan emphasized the company's commitment to long-term value creation and expressed optimism about future developments. Recursion is focused on advancing its investigational medicines across various therapeutic areas using its AI-powered platform. The organization's infrastructure supports its mission to translate complex science into effective therapies.
Read more →RXRXRecursion To Report First Quarter 2026 Business Updates And Financial Results On May 6
Recursion To Report First Quarter 2026 Business Updates And Financial Results On May 6
Read more →RXRX▲ +8.1%on this news
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Recursion has announced an expansion of its strategic partnership with Citeline, aiming to enhance its AI-enabled ClinTech platform. This collaboration integrates Citeline’s real-world data capabilities, supporting more precise trial designs and improved decision-making in drug development. The CEO of Recursion noted that this partnership has already led to significant improvements in enrollment rates for clinical trials. The overall goal is to create a more connected and patient-centered biopharmaceutical ecosystem.
Read more →RXRXRecursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Recursion has appointed Dr. Vicki Goodman as its new Chief Medical Officer, effective April 6, 2026. She succeeds Dr. David Mauro, who has served in the role for three years. Dr. Goodman brings over two decades of experience in oncology and drug development, which is expected to significantly benefit Recursion's clinical programs and pipeline advancements.
Read more →About Recursion Pharmaceuticals, Inc.
Headquarters41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
BIOPHARMAWATCH ELITE PLUS
Trade the next RXRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime